XOMA

85 articles about XOMA

• XOMA Declares Quarterly Preferred Stock Dividends - June 20, 2022

  6/20/2022

  XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA to Present at H.C. Wainwright Global Investment Conference

  5/17/2022

  XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 10:00 AM ET.

• XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

  5/5/2022

  XOMA Corporation reported its first quarter 2022 financial results and provided a recent operations update.

• XOMA Declares Quarterly Preferred Stock Dividends - Mar 21, 2022

  3/21/2022

  XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA to Present at Oppenheimer’s 32nd Annual Healthcare Conference

  3/10/2022

  XOMA Corporation announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer’s 32nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET.

• XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events

  3/8/2022

  XOMA Corporation, a biotech royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, reported its 2021 financial results and provided a recent operations update.

• XOMA to Present at the 42nd Annual Cowen Health Care Conference

  3/1/2022

  XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will be featured in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 1:30 PM ET.

• XOMA to Present at Aegis Capital Corp Investor Conference

  2/17/2022

  XOMA Corporation announced today its Chief Executive Officer, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET. 

• 

  Predicting the Life Sciences Investment Market in 2022

  1/6/2022

  Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022. 

• XOMA Declares Quarterly Preferred Stock Dividends - Dec 23, 2021

  12/23/2021

  XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA to Present at Upcoming Investor Conferences - Dec 21, 2021

  12/21/2021

  XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences:

• XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events

  11/4/2021

  XOMA Corporation reported its third quarter 2021 financial results and provided a recent operations update.

• XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer

  11/4/2021

  XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3 development stage, triggering a $35 million milestone payment from Novartis. 

• XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

  9/22/2021

  XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT.

• XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  9/13/2021

  XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference held on September 13-15, 2021. 

• XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events

  8/5/2021

  XOMA Corporation reported its second quarter 2021 financial results and provided a recent operations update.

• XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

  7/15/2021

  XOMA Corporation, announced it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod, an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones.

• XOMA Declares Quarterly Preferred Stock Dividends

  6/21/2021

  XOMA Corporation today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:

• XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting

  5/21/2021

  XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 4-8, 2021, in a virtual setting.

• XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

  5/3/2021

  XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets.